Cover Image

Comparative effectiveness and acceptability of HIF prolyl-hydroxylase inhibitors versus for anemia patients with chronic kidney disease undergoing dialysis: a systematic review and network meta-analysis

Background: The comparative benefits and acceptability of HIF-PHIs for treating anemia have not been well researched to date. We sought to compare the effectiveness of 6 HIF-PHIs and 3 ESAs for the treatment of renal anemia patients undergoing dialysis.Data sources: Cochrane Central Register of Cont...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qiong Huang (Author), Minling You (Author), Weijuan Huang (Author), Jian Chen (Author), Qinming Zeng (Author), Longfeng Jiang (Author), Xiuben Du (Author), Xusheng Liu (Author), Ming Hong (Author), Jing Wang (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
by: Dinghua Chen, et al.
Published: (2023)

HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
by: Andrey A. Poloznikov, et al.
Published: (2021)

Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
by: Maria Savyuk, et al.
Published: (2020)

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
by: Amit A. Joharapurkar, et al.
Published: (2022)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
by: Li Zheng, et al.
Published: (2022)

Inhibition of prolyl hydroxylases increases hepatic insulin and decreases glucagon sensitivity by an HIF-2α-dependent mechanism
by: Matthew Riopel, et al.
Published: (2020)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
by: Jing Li, et al.
Published: (2022)

Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice
by: Shunji Nishide, et al.
Published: (2020)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
by: Jie Lun, et al.
Published: (2023)

Efficacy of novel drugs hypoxia inducible factor prolyl hydroxylase inhibitor in therapy of posttransplant anemia. A review
by: Piotr Pawlowski, et al.
Published: (2024)

Therapeutic Effect of Extracellular Vesicles Derived from HIF Prolyl Hydroxylase Domain Enzyme Inhibitor-Treated Cells on Renal Ischemia/Reperfusion Injury
by: Zhao-Ying Ding, et al.
Published: (2022)

Human prolyl hydroxylase expression in uterine leiomyoma during the menstrual cycle
by: Iwahashi Masaaki, et al.
Published: (2012)

Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Prolyl-Hydroxylase Inhibitors to Activate Hypoxia-Inducible Factor (HIF) as a Novel Therapeutic Approach in CKD
by: Tetsuhiro Tanaka, et al.
Published: (2009)

Exploring the natural products chemical space through a molecular search to discover potential inhibitors that target the hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD)
by: Abrar Mohammad Sayaf, et al.
Published: (2023)

Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses
by: Song Ren, et al.
Published: (2023)

Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis
by: Song Ren, et al.
Published: (2024)

Structure-Activity Relationships and Transcriptomic Analysis of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
by: Andrey A. Poloznikov, et al.
Published: (2022)

Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases
by: Mengqiu Miao, et al.
Published: (2022)

Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
by: Yu-Hsiang Chou, et al.
Published: (2023)

Dysfunction of von-Hippel Lindau factor causes reduced degradation of HIF leading to renal cancer. Hypoxia-inducible factor-prolyl hydroxylase enzyme inhibitors also lessen HIF destruction and could therefore increase renal cancer
by: Helge Waldum
Published: (2023)

Thrombospondin-1 and prolyl 4-hydroxylase subunit alpha 3 as potential biomarkers of salivary gland fibrosis
by: Zijian Zhang, et al.
Published: (2023)

Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotally nephrectomized rats
by: Anqi Zhang, et al.
Published: (2021)

Prolyl-hydroxylase inhibitor-induced regeneration of alveolar bone and soft tissue in a mouse model of periodontitis through metabolic reprogramming
by: Elan Zebrowitz, et al.
Published: (2022)

Interest of HIF stabilizers in home dialysis
by: Guy Rostoker
Published: (2023)

Suppression of collagen IV alpha‐2 subunit by prolyl hydroxylase domain inhibition via hypoxia‐inducible factor‐1 in chronic kidney disease
by: Mohammad Sanaei‐Ardekani, et al.
Published: (2021)

Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model
by: Kazuya Kabei, et al.
Published: (2020)

Hypoxia-Inducible Factor-Proline Hydroxylase Inhibitor in the Treatment of Renal Anemia
by: Xiaofan Hu, et al.
Published: (2020)

Role of anuria in the relationship between indoxyl sulfate and anemia in peritoneal dialysis patients
by: Huang JY, et al.
Published: (2016)

Iron supplements concomitant with HIF-PHIs in the treatment of CKD anemia
by: Xue Wang, et al.
Published: (2023)

Editorial: Peptidyl-Prolyl Isomerases in Human Pathologies
by: Tiziano Tuccinardi, et al.
Published: (2019)

Assessment of Adequacy of Dialysis in Patients Undergoing Dialysis With Bicarbonate Solution
by: Ehteram Sadat Ilali, et al.
Published: (2011)

Assessment of Adequacy of Dialysis in Patients Undergoing Dialysis with Bicarbonate Solution
by: Raheleh Mohseni, et al.
Published: (2012)

Association between ambient carbon monoxide and secondary hyperparathyroidism in nondiabetic patients undergoing peritoneal dialysis
by: Weng CH, et al.
Published: (2015)

2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione Ameliorates Diabetic Cognitive Impairment Through Inhibiting Hif3α and Apoptosis
by: Lihui Wang, et al.
Published: (2021)

Endocrine profiles and cycle characteristics of infertile 17α-hydroxylase/17,20-lyase Deficiency Patients undergoing assisted Reproduction Treatment: a retrospective cohort study
by: Ping Pan, et al.
Published: (2023)

Prolyl Endopeptidase-like Deficiency Associated with Growth Hormone Deficiency
by: Laura Sayol-Torres, et al.
Published: (2023)

Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice
by: Lei Li, et al.
Published: (2020)

Asymptomatic Supraventricular Arrhythmias in Patients Undergoing Dialysis
by: O. V. Likhachev-Mishchenko, et al.
Published: (2021)

Risk Factors and Clinical Outcomes of Cognitive Impairment in Diabetic Patients Undergoing Peritoneal Dialysis
by: Xuan Huang, et al.
Published: (2021)

Decreased plasma levels of PDGF-BB, VEGF-A, and HIF-2α in preterm infants after ibuprofen treatment
by: Xuemei Huang, et al.
Published: (2022)